Compare RGEN & PSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGEN | PSO |
|---|---|---|
| Founded | 1981 | 1844 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Books |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 8.9B |
| IPO Year | N/A | 2000 |
| Metric | RGEN | PSO |
|---|---|---|
| Price | $166.48 | $14.13 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $174.90 | N/A |
| AVG Volume (30 Days) | 617.0K | ★ 694.3K |
| Earning Date | 02-19-2026 | 03-03-2026 |
| Dividend Yield | N/A | ★ 2.31% |
| EPS Growth | N/A | ★ 31.65 |
| EPS | 0.03 | ★ 0.90 |
| Revenue | $707,890,000.00 | ★ $4,822,578,436.00 |
| Revenue This Year | $17.84 | $2.36 |
| Revenue Next Year | $12.44 | $5.20 |
| P/E Ratio | $6,513.01 | ★ $15.72 |
| Revenue Growth | ★ 11.74 | N/A |
| 52 Week Low | $102.97 | $12.85 |
| 52 Week High | $182.52 | $17.90 |
| Indicator | RGEN | PSO |
|---|---|---|
| Relative Strength Index (RSI) | 58.72 | 63.44 |
| Support Level | $161.41 | $14.05 |
| Resistance Level | $167.65 | $14.23 |
| Average True Range (ATR) | 4.54 | 0.12 |
| MACD | 0.16 | 0.04 |
| Stochastic Oscillator | 89.26 | 84.85 |
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
UK-listed Pearson is a testing and educational provider. Pearson's primary operations are in assessment and qualification testing and higher education, but they also provide English education and testing, virtual learning, prehiring testing and screening, and upskilling/reskilling. The company divested noncore businesses, including the Financial Times, The Economist, and publishing house Penguin, and is now focused on being an educational resource and testing provider.